131I effective half-life (Teff) for patients with thyroid cancer.

Nuclear medicine procedures that use I activity represent significant sources of potential absorbed dose to medical staff, volunteers, and the general public. The potential exposures are due principally from exposures to excreted and retained activities in the patients' bodies. In general, exposure rate decreases in a simple exponential manner.

[Radioiodine therapy for differentiated thyroid carcinoma: methods used to increase the radiation absorbed dose].

Objectives: Our aim was to analyze measures taken to increase the radiation absorbed dose (DOSE) during treatment of well-differentiated thyroid cancer (DTC) with iodine-131.

Methods: An increase in DOSE is achieved by: avoiding competition with non-radioactive iodine, stimulating cellular uptake/retention, increasing the administered activity. Basis and results of each one of these methods were reviewed.